Skip to main content

Advertisement

Table 8 Scenario analysis

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

  Overall num. Patients Num. patients treated with efmoroctocog alfa Cost CE (Euro) Cost NE (Euro) Savings (Euro) % Savings
Scenario 1 3525 529 755,189,490 736,992,099 18,197,391 2.4%
Scenario 2 4284 474 693,489,851 690,835,256 2,654,595 0.4%